ANI Pharmaceuticals (FRA:BSFA) Tariff Resilience Score: 7/10 (As of Aug. 08, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:BSFA ANI Pharmaceuticals Inc FRA:BSFA
78 GF Score
Price €66.00
GF Value €83.99
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is ANI Pharmaceuticals Tariff Resilience Score?

ANI Pharmaceuticals FRA:BSFA -2.94% 78 Tariff Resilience Score is 7 as of Aug. 08, 2026. GuruFocus rates FRA:BSFA with a GF Score™ of 78/100 and a GF Value™ of €83.99 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 1,026 Drug Manufacturers companies, ANI Pharmaceuticals ranks better than 97.08% on this metric.

ANI Pharmaceuticals has the Tariff Resilience Score of 7, which implies that the company might have Highly Resilient.

ANI Pharmaceuticals has ANI Pharmaceuticals Inc has moderate tariff exposure due to its pharmaceutical imports. However, the company benefits from industry-specific exemptions and has strong pricing power. Historical tariffs have had limited impact, and it can source from alternative suppliers.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes ANI Pharmaceuticals might have Highly Resilient.

ANI Pharmaceuticals  (FRA:BSFA) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

ANI Pharmaceuticals Tariff Resilience Score Related Terms

FRA:BSFA vs TRLV, AMLX, XERS: Tariff Resilience Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, ANI Pharmaceuticals's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ANI Pharmaceuticals Tariff Resilience Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, ANI Pharmaceuticals's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where ANI Pharmaceuticals's Tariff Resilience Score falls into.


FRA:BSFA
78GF Score
ANI Pharmaceuticals Inc FRA:BSFA
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 7 mean?
ANI Pharmaceuticals (FRA:BSFA) has a Tariff Resilience Score of 7 as of Aug. 08, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, ANI Pharmaceuticals ranks #30 out of 1026 companies in the Drug Manufacturers industry, placing it in the top 2.9%.
Is ANI Pharmaceuticals' Tariff Resilience Score too high?
ANI Pharmaceuticals' current Tariff Resilience Score is 7. Based on the distribution chart, ANI Pharmaceuticals ranks #30 out of 1026 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, ANI Pharmaceuticals has a GF Score™ of 78/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ANI Pharmaceuticals' Tariff Resilience Score compare to TRLV and AMLX?
According to the Drug Manufacturers industry distribution chart, ANI Pharmaceuticals ranks #30 out of 1026 companies for Tariff Resilience Score. This places ANI Pharmaceuticals in the top 3% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Drug Manufacturers company?
A good Tariff Resilience Score depends on the Drug Manufacturers industry context. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. ANI Pharmaceuticals's current Tariff Resilience Score is 7. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ANI Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, ANI Pharmaceuticals (FRA:BSFA) is currently considered Modestly Undervalued. The stock's GF Value™ is €83.99, compared to a current price of €66.00 — trading 21.4% below its estimated fair value. The current Tariff Resilience Score is 7. ANI Pharmaceuticals' overall GF Score™ is 78/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For ANI Pharmaceuticals (FRA:BSFA), the current Tariff Resilience Score is 7 as of Aug. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ANI Pharmaceuticals (FRA:BSFA) Overvalued in 2026?

Based on GuruFocus' analysis, ANI Pharmaceuticals stock appears to be undervalued. The current stock price of €66.00 is trading 21.4% below its estimated GF Value™ of €83.99. GuruFocus considers ANI Pharmaceuticals to be Modestly Undervalued.

Key valuation signals for FRA:BSFA:

  • Tariff Resilience Score: 7
  • GF Value™: €83.99 vs. price of €66.00 (21.4% below fair value)
  • GF Score™: 78/100 with 2 warning signs

No single metric tells the full story. See the FRA:BSFA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ANI Pharmaceuticals Business Description

Other Exchanges ANIP:USA
Address 210 Main Street West, Baudette, MN, USA, 56623
ANI Pharmaceuticals Inc is a diversified biopharmaceutical company. It is focused on developing, manufacturing, and commercializing therapeutics through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; and through its Generics and Brands businesses. The firm's product portfolio comprises Purified Cortrophin Gel, ILUVIEN, and YUTIQ (fluocinolone acetonide intravitreal implant), among others. Additionally, its Generics portfolio includes several products with a wide variety of indications. The company has two operating segments: Rare Disease and Brands, which derive maximum revenue, and Generics and Other. Geographically, it generates maximum revenue from the United States, followed by other markets.
78GF Score

Get the complete analysis for FRA:BSFA

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€66.00
Price
€83.99
GF Value